Universal Donor Natural Killer Cells and ALT-803 in Treating Patients with Relapsed or Refractory Blood Cancer, Colon / Rectal Cancer, or Soft Tissue Sarcoma
- Patients must have histologic confirmation of relapsed and or refractory hematologic malignancy, locally advanced or metastatic colon/rectal carcinoma, or refractory and/or relapsed soft tissue sarcomas and have failed at least one standard line of therapy; patients will be eligible if they have either declined standard treatment regimens or if there is no standard approach to curative salvage therapy per National Comprehensive Cancer Network (NCCN) guidelines in the setting of relapsed/refractory disease; in addition, patients for whom a potential 29-day delay in treatment will not interfere with the subject’s potential therapeutic options can be eligible per the treating physician's discretion Malignancies can include: * Acute myeloid leukemia * Myelodysplastic syndrome * Acute lymphoblastic leukemia * Chronic myeloid leukemia * Chronic lymphocytic leukemia * Non Hodgkin lymphoma * Hodgkin lymphoma * Myeloproliferative syndromes * Plasma cell myeloma * Colon/rectal carcinoma * Sarcomas including but not limited to Ewing’s sarcoma and rhabdomyosarcoma
- Patients must have recovered from acute toxicities of prior chemotherapy or stem cell transplant; any prior non-hematologic vital organ toxicity (cardiac, pulmonary, hepatic, renal) of previous therapy must have resolved to grade 1 or less
- All previous chemotherapy, immunologic therapy or radiation must be completed at least 3 weeks prior to study entry. Patients with prior stem cell transplant must be greater than 365 days post-transplant
- Eastern Cooperative Oncology Group performance status (ECOG PS) =< 2
- Serum total bilirubin < 2 mg/dl (except if known Gilbert syndrome AND normal transaminases)
- Aspartate aminotransferases (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) < 2.5 x institutional upper limit of normal
- Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x institutional upper limit of normal
- Pulmonary function (diffusion capacity of the lung for carbon monoxide [DLCO]) > 40% of the expected value corrected for alveolar volume and hemoglobin
- Serum creatinine =< 1.5 x institutional upper limit of normal
- Subjects must have the ability to understand and the willingness to sign a written informed consent document
- Women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 4 weeks prior to study entry and for the duration of study participation; women of child-bearing age must have documented negative pregnancy test prior to start of lympho-depleting regimen
- Subjects receiving any other investigational agents
- Subjects for whom a potential 29-day delay in treatment will interfere with the subject’s potential therapeutic options
- Patients with untreated malignant involvement of the central nervous system (CNS) should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events; head imaging will be necessary to document absence of CNS involvement in patients with colon/rectal cancer and soft tissue sarcomas; patients with hematologic malignancies who have undergone treatment for malignant involvement of the CNS must have no evidence of residual disease by imaging or cerebrospinal fluid (CSF) sampling prior to study enrollment
- History of allergic reactions to chemotherapy agents used in this protocol as part of lymphodepletion regimen (fludarabine and cyclophosphamide)
- Patients with uncontrolled intercurrent illness including, but not limited to ongoing active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant or breastfeeding women are excluded from this study, because cytotoxic agents used as part of lymphodepletion in this protocol have the potential for teratogenic or abortifacient effects; because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with the agents described above, breastfeeding should be discontinued if the mother participates in this trial
- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with chemotherapeutic agents; in addition, these patients are at increased risk of lethal infections when treated with marrow suppressive therapy
- Chronic active untreated hepatitis B or C infection. (Assessments should include hepatitis B surface antibody [AB], hepatitis B surface antigen [AG], hepatitis B core AB - total, hepatitis B core AB, IGM, hepatitis C AB)
- Recipients of previous allogeneic transplants who have rash involving more than 10% body surface area attributed to graft versus host disease (GVHD) (> grade 1 GVHD of skin); stem cell transplant recipients will be excluded if they are still receiving immunosuppression including steroids for GVHD or have active GVHD in any organ (except for grade 1 only of skin, not requiring treatment)
I. To determine the maximum tolerated dose of ex vivo expanded non-human leukocyte antigen (HLA) matched donor natural killer (NK) cells in combination with ALT-803.
I. Describe safety profile / toxicity of combining ALT-803 with NK cell adoptive therapy.
II. Determine antitumor activity of allogeneic NK cells with ALT-803 support.
III. Determine if a lymphocyte depleting regimen is adequate for preventing early elimination of HLA-mismatched donor NK cells by host T-cells.
OUTLINE: This is a dose escalation study of natural killer cells.
PREPARATIVE REGIMEN: Patents receive cyclophosphamide intravenously (IV) and mesna IV on day -7 and fludarabine phosphate IV over 30 minutes daily (QD) on days -6 to -2.
NK CELL INFUSION: Patients receive NK cells IV on day 0 and day 14. Patients also receive superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex ALT-803 subcutaneously (SC) on days 0 and 14.
After completion of study treatment, patients are followed up at 28 days, 100 days, 6 months, and 12 months after the first NK cell infusion.
Trial Phase Phase I
Trial Type Treatment
Case Comprehensive Cancer Center
- Primary ID CASE2Z16
- Secondary IDs NCI-2017-00305
- Clinicaltrials.gov ID NCT02890758